Common Contracts
4 similar Registration Rights Agreement contracts by Oscient Pharmaceuticals Corp, Affymetrix Inc, Delta Air Lines Inc /De/
OSCIENT PHARMACEUTICALS CORPORATION 3½% Senior Convertible Notes due 2011 REGISTRATION RIGHTS AGREEMENT May 10, 2004Registration Rights Agreement • August 9th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • New York
Oscient Pharmaceuticals Corporation, a Massachusetts corporation (the “Company”), proposes to issue and sell (such issuance and sale, the “Initial Placement”) to the Initial Purchasers (as defined below), upon the terms set forth in a purchase agreement, dated May 4, 2004 (the “Purchase Agreement”), $125,000,000 aggregate principal amount, plus an option (the “Option”) to purchase up to an additional $18,750,000 aggregate principal amount, of its 3½% Senior Convertible Notes due 2011 (the “Securities”). The Securities will be convertible into shares of Common Stock (as defined herein), at the conversion price set forth in the Offering Memorandum (as defined herein), as the same may be adjusted from time to time pursuant to the Indenture (as defined herein). As an inducement to you to enter into the Purchase Agreement and in satisfaction of a condition to your obligations thereunder, the Company agrees with you, (i) for your benefit and (ii) for the benefit of the Holders (as defined he
OSCIENT PHARMACEUTICALS CORPORATION 3½% Senior Convertible Notes due 2011 REGISTRATION RIGHTS AGREEMENT May 25, 2004Registration Rights Agreement • August 9th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • New York
Oscient Pharmaceuticals Corporation, a Massachusetts corporation (the “Company”), proposes to issue and sell (such issuance and sale, the “Initial Placement”) to the Initial Purchaser (as defined below), upon the terms set forth in a purchase agreement, dated May 25, 2004 (the “Purchase Agreement”), $6,000,000 aggregate principal amount, plus an option, subject to the terms and conditions of the Purchase Agreement, (the “Option”) to purchase up to an additional $3,000,000 aggregate principal amount, of its 3½% Senior Convertible Notes due 2011 (the “Securities”). The Securities will be convertible into shares of Common Stock (as defined herein), at the conversion price set forth in the Offering Memorandum (as defined herein), as the same may be adjusted from time to time pursuant to the Indenture (as defined herein). As an inducement to you to enter into the Purchase Agreement and in satisfaction of a condition to your obligations thereunder, the Company agrees with you, (i) for your b
DELTA AIR LINES, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 5th, 2004 • Delta Air Lines Inc /De/ • Air transportation, scheduled • New York
Delta Air Lines, Inc., a Delaware corporation (the “Company”), proposes to issue and sell (such issuance and sale, the “Initial Placement”) to Morgan Stanley & Co. Incorporated (the “Initial Purchaser”), upon the terms set forth in a purchase agreement, dated February 2, 2004 (the “Purchase Agreement”), $325,000,000 aggregate principal amount, plus an option (the “Option”) to purchase up to an additional $65,000,000 aggregate principal amount, of its 2 7/8% Convertible Senior Notes due 2024 (the “Securities”). The Securities will be convertible into shares of Common Stock (as defined herein), at the conversion rate set forth in the Offering Memorandum (as defined herein), as the same may be adjusted from time to time pursuant to the Indenture (as defined herein). As an inducement to you to enter into the Purchase Agreement and in satisfaction of a condition to your obligations thereunder, the Company agrees with you, (i) for your benefit and (ii) for the benefit of the Holders (as defi
AFFYMETRIX, INC.Registration Rights Agreement • January 29th, 2004 • Affymetrix Inc • Laboratory analytical instruments • New York
Affymetrix, Inc., a Delaware corporation (the “Company”), proposes to issue and sell (such issuance and sale, the “Initial Placement”) to the Initial Purchasers (as defined below), upon the terms set forth in a purchase agreement, dated December 10, 2003 (the “Purchase Agreement”), $100,000,000 aggregate principal amount, plus an option (the “Option”) to purchase up to an additional $20,000,000 aggregate principal amount, of its 0.75% Senior Convertible Notes due 2033 (the “Securities”). The Securities will be convertible into shares of Common Stock (as defined herein), at the conversion price set forth in the Offering Memorandum (as defined herein), as the same may be adjusted from time to time pursuant to the Indenture (as defined herein). As an inducement to you to enter into the Purchase Agreement and in satisfaction of a condition to your obligations thereunder, the Company agrees with you, (i) for your benefit and (ii) for the benefit of the Holders (as defined herein) from time
